The European Medicines Agency (EMA) has recommended the approval of Mirikizumab, developed by Eli Lilly, for the treatment of adults with moderately to severely active ulcerative colitis. This decision follows a comprehensive review of clinical trial data demonstrating the therapy's efficacy and safety profile.

Mirikizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a key cytokine involved in inflammatory processes. The positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) marks a significant step toward expanding treatment options for patients in Europe living with this chronic inflammatory bowel disease.

The final decision on marketing authorization will be made by the European Commission in the coming months. If approved, Mirikizumab will offer a new therapeutic option for healthcare professionals managing ulcerative colitis.